Beyond Air, Inc. (XAIR)

USD 0.43

(-5.41%)

Market Cap (In USD)

31.06 Million

Revenue (In USD)

1.15 Million

Net Income (In USD)

-60.24 Million

Avg. Volume

555.77 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.296-2.36
PE
-
EPS
-
Beta Value
-0.182
ISIN
US08862L1035
CUSIP
08862L103
CIK
1641631
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Steven Adam Lisi
Employee Count
-
Website
https://www.beyondair.net
Ipo Date
2018-06-12
Details
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.